Go offline with the Player FM app!
1.26 - Current Status of Psychedelics in Psychiatry: A Brief Review of Clinical Research by Treatment Condition
Manage episode 360208502 series 2896878
This podcast discusses the current state of research on the use of psychedelics in psychiatry, especially psilocybin, for the treatment of depression and other mental illnesses, including the precautions that must be taken before treatment, the standardized four-stage treatment model for depression, and the obstacles that must be overcome to use psychedelic therapy on a larger scale.
Current Status of Psychedelics in Psychiatry (D Nutt & R Cahart-Harris)
Support the podcast
Certificate in Psychedelic Assisted Therapies
Donate to Mind Medicine Australia
In this episode:
- The podcast reviews the clinical research on the use of psychedelics in psychiatry, including the history of psychedelic research, recent developments, and the potential of psilocybin as a treatment for various mental illnesses.
- Psilocybin may be useful in treating depression and has been shown to have antidepressant effects on people with resistant depression, anxiety, and depression symptoms caused by life-threatening cancer diagnoses, as well as in treating alcohol and tobacco dependence.
- Certain precautions must be taken before treatment, such as assessing whether the patient is suitable for psychedelic therapy and stopping medications that block or attenuate the effects of the psychedelic.
- Psychedelic therapy involves a standardized four-stage process for depression treatment, which includes assessment, preparation, experience, and integration.
- One of the main obstacles to using psychedelic therapy on a larger scale is the current resource-intensive model, which requires high-quality training and practice.
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
50 episodes
Manage episode 360208502 series 2896878
This podcast discusses the current state of research on the use of psychedelics in psychiatry, especially psilocybin, for the treatment of depression and other mental illnesses, including the precautions that must be taken before treatment, the standardized four-stage treatment model for depression, and the obstacles that must be overcome to use psychedelic therapy on a larger scale.
Current Status of Psychedelics in Psychiatry (D Nutt & R Cahart-Harris)
Support the podcast
Certificate in Psychedelic Assisted Therapies
Donate to Mind Medicine Australia
In this episode:
- The podcast reviews the clinical research on the use of psychedelics in psychiatry, including the history of psychedelic research, recent developments, and the potential of psilocybin as a treatment for various mental illnesses.
- Psilocybin may be useful in treating depression and has been shown to have antidepressant effects on people with resistant depression, anxiety, and depression symptoms caused by life-threatening cancer diagnoses, as well as in treating alcohol and tobacco dependence.
- Certain precautions must be taken before treatment, such as assessing whether the patient is suitable for psychedelic therapy and stopping medications that block or attenuate the effects of the psychedelic.
- Psychedelic therapy involves a standardized four-stage process for depression treatment, which includes assessment, preparation, experience, and integration.
- One of the main obstacles to using psychedelic therapy on a larger scale is the current resource-intensive model, which requires high-quality training and practice.
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
50 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.